{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02309762",
      "orgStudyIdInfo": {
        "id": "FB825CLCT01"
      },
      "organization": {
        "fullName": "Fountain Biopharma Inc.",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers",
      "officialTitle": "A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Ascending Intravenous Doses of FB825"
    },
    "statusModule": {
      "statusVerifiedDate": "2016-02",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2015-03"
      },
      "primaryCompletionDateStruct": {
        "date": "2016-02",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2016-02",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2014-11-14",
      "studyFirstSubmitQcDate": "2014-12-03",
      "studyFirstPostDateStruct": {
        "date": "2014-12-05",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2016-02-03",
      "lastUpdatePostDateStruct": {
        "date": "2016-02-04",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Fountain Biopharma Inc.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single-ascending IV doses of FB825"
    },
    "conditionsModule": {
      "conditions": [
        "Healthy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "DOUBLE",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 54,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "FB825",
          "type": "EXPERIMENTAL",
          "description": "6 cohorts of subjects are planned to be dosed by IV injection, with single- ascending doses ranging from 0.003 - 10 mg/kg",
          "interventionNames": [
            "Drug: FB825"
          ]
        },
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Placebo",
          "interventionNames": [
            "Drug: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "FB825",
          "description": "FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection",
          "armGroupLabels": [
            "FB825"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Solution containing no active ingredients",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of Participants with Adverse events (AE)",
          "timeFrame": "Up to day140"
        },
        {
          "measure": "Clinical laboratory test results (hematology, coagulation, serum chemistry[including liver function tests], and urinalysis)",
          "timeFrame": "Up to day140"
        },
        {
          "measure": "Vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and oral body temperature)",
          "timeFrame": "Up to day140"
        },
        {
          "measure": "12-lead ECG results",
          "timeFrame": "Up to day140"
        },
        {
          "measure": "Physical examination findings",
          "timeFrame": "Up to day140"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Composite of PK parameters",
          "description": "Blood will be collected for the determination of serum FB825 concentrations, Cmax, Tmax, AUC, and terminal half-life.These parameters will be determined using non-compartmental methods.",
          "timeFrame": "Pre-dose, 2, 3, 5, 14, 29, 85, and 140 day post-dose"
        },
        {
          "measure": "Total IgE serum concentrations",
          "description": "Blood will be collected to measure serum IgE concentrations.",
          "timeFrame": "pre-dose, 5, 14, 29, 85, and 140 day post-dose"
        },
        {
          "measure": "Immunogenicity (Anti-FB825 antibody in serum)",
          "description": "Blood will be collected to measure Immunogenicity.",
          "timeFrame": "pre-dose, 5, 14, 29, 85, and 140 day post-dose"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. The subject is male or female between 18 and 55 years of age, inclusive.\n2. All female subjects must have a negative serum pregnancy test at screening and on Day -1.\n3. The subject has a body weight â‰¥50 kg at screening and a body mass index of 18 to 30 kg/m2, inclusive.\n4. The subject has a good health condition based upon the results of medical history, physical examination, vital signs, laboratory profile and ECG.\n5. The subject has a negative urine drug screen for alcohol, cotinine.\n\nExclusion Criteria:\n\n1. Female subjects who are pregnant or lactating.\n2. The subject has a past history of heart arrhythmias.\n3. The subject has history of clinically significant diseases.\n4. The subject has any history of a previous anaphylactic reaction.\n5. Use of prescribed medication within 6 months of Day -1.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "55 Years",
      "stdAges": [
        "ADULT"
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    }
  },
  "hasResults": false
}